European Commission approves expanded age indication for GSK’s Arexvy, the first respiratory syncytial virus (RSV) vaccine for adults aged 50-59 at increased risk Read more
Aptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop Tuspetinib Read more
Lilly releases Zepbound (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity Read more
EC Approves Astellas’ PADCEVTM (enfortumab vedotin) in Combination with KEYTRUDA (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer Read more
Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH Read more
UCB to Accelerate Innovation and Strategic Partnerships, Divesting Mature Product Portfolio in China Read more